0.375
price down icon10.71%   -0.045
after-market After Hours: .38 0.005 +1.33%
loading
Avenue Therapeutics Inc stock is traded at $0.375, with a volume of 173.84K. It is down -10.71% in the last 24 hours and down -73.59% over the past month. Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
See More
Previous Close:
$0.42
Open:
$0.38
24h Volume:
173.84K
Relative Volume:
0.44
Market Cap:
$770.22K
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.0984
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
-60.34%
1M Performance:
-73.59%
6M Performance:
-85.63%
1Y Performance:
-96.88%
1-Day Range:
Value
$0.3521
$0.4195
1-Week Range:
Value
$0.3521
$0.973
52-Week Range:
Value
$0.3521
$12.53

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Name
Name
Avenue Therapeutics Inc
Name
Phone
781-652-4500
Name
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Name
Employee
3
Name
Twitter
@avenuethera
Name
Next Earnings Date
2024-12-11
Name
Latest SEC Filings
Name
ATXI's Discussions on Twitter

Compare ATXI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATXI
Avenue Therapeutics Inc
0.375 770.22K 0 -10.38M -12.45M -3.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Avenue Therapeutics Inc Stock (ATXI) Latest News

pulisher
Mar 18, 2025

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

United States shares lower at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025
pulisher
Mar 17, 2025

Atlanticus Holdings Co. 9.25% Senior Notes due 2029 (NASDAQ:ATLCZ) Short Interest Update - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Decline in Short Interest - Defense World

Mar 17, 2025
pulisher
Mar 15, 2025

AVENUE THERAPEUTICS Earnings Preview: Recent $ATXI Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 15, 2025
pulisher
Mar 14, 2025

Avenue Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

Postoperative Pain Clinical Pipeline | 45+ Companies, - openPR

Mar 14, 2025
pulisher
Mar 13, 2025

Avenue Therapeutics stock hits 52-week low at $0.9 amid downturn - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Mar 13, 2025
pulisher
Mar 12, 2025

Episode 203Curtis Oltmans - Audacy

Mar 12, 2025
pulisher
Mar 07, 2025

Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Avenue Therapeutics granted Nasdaq extension, faces AnnJi dispute - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Avenue Therapeutics Annji Intends To Terminate License Agreement With Co -March 07, 2025 at 04:36 pm EST - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online

Mar 07, 2025
pulisher
Mar 05, 2025

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - Nasdaq

Mar 05, 2025
pulisher
Mar 04, 2025

SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow

Mar 04, 2025
pulisher
Mar 03, 2025

Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

KESTRA MEDICAL TECHNOLOGIES, LTD. Prices IPO at $14.00-$16.00 Per Share (KMTS) - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Arbe Robotics Ltd. (NASDAQ:ARBE) Short Interest Up 56.5% in February - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics stock hits 52-week low at $1.22 - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics (NASDAQ:ATXI) vs. Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World

Feb 28, 2025
pulisher
Feb 12, 2025

The Surprise Surge: How Travere Therapeutics Defied Wall Street Trends - Jomfruland.net

Feb 12, 2025
pulisher
Feb 12, 2025

Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

ATXIAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - br.ADVFN.com

Feb 11, 2025
pulisher
Feb 06, 2025

Sionna Therapeutics Prices Upsized Initial Public Offering - GlobeNewswire

Feb 06, 2025
pulisher
Feb 05, 2025

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance

Feb 05, 2025
pulisher
Feb 05, 2025

Here’s Why Third Avenue Small-Cap Value Fund Re-established a Position in Five Point Holdings (FPH) - Yahoo Finance

Feb 05, 2025
pulisher
Jan 28, 2025

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 28, 2025

Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com

Jan 28, 2025
pulisher
Jan 27, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 27, 2025
pulisher
Jan 27, 2025

Trajan Group Director Increases Stake Through Options - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Jan 26, 2025
pulisher
Jan 26, 2025

Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025

Avenue Therapeutics Inc Stock (ATXI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):